drug · small molecule
lenvatinib mesylate
Marketedupdated 5mo agoby Eisai Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.
indications
investigational
Colorectal CancerMelanoma
targets
Vascular endothelial growth factor receptor
all catalysts(2)
Trials studying lenvatinib mesylate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 19, 2027
160 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (40)
- Nov 15, 2038patentUS 12226409*PED
- Nov 15, 2038patentUS 12226409*PED
- May 15, 2038method-of-use (U-4146)US 12226409
- May 15, 2038method-of-use (U-4146)US 12226409
- Sep 3, 2036patentUS 12083112*PED
- Sep 3, 2036patentUS 12083112*PED
- Aug 23, 2036patentUS 11090386*PED
- Aug 23, 2036patentUS 11090386*PED
- Mar 3, 2036method-of-use (U-3997)US 12083112
- Mar 3, 2036method-of-use (U-3997)US 12083112
- Feb 26, 2036patentUS 10259791*PED
- Feb 26, 2036patentUS 10259791*PED
- Feb 26, 2036patentUS 10407393*PED
- Feb 26, 2036patentUS 10407393*PED
- Feb 26, 2036patentUS 11186547*PED
- Feb 26, 2036patentUS 11186547*PED
- Feb 23, 2036method-of-use (U-3519)US 11090386
- Feb 23, 2036method-of-use (U-3519)US 11090386
- Aug 26, 2035compositionUS 10259791
- Aug 26, 2035compositionUS 10259791
- Aug 26, 2035compositionUS 10407393
- Aug 26, 2035compositionUS 10407393
- Aug 26, 2035compositionUS 11186547
- Aug 26, 2035compositionUS 11186547
- Apr 4, 2031patentUS 12508313*PED4.5y
- Apr 4, 2031patentUS 12508313*PED4.5y
- Oct 4, 2030formulationUS 125083134.0y
- Oct 4, 2030formulationUS 125083134.0y
- Jan 27, 2028patentUS 9006256*PED1.3y
- Jan 27, 2028patentUS 9006256*PED1.3y
- Jul 27, 2027method-of-use (U-1695)US 9006256290d
- Jul 27, 2027method-of-use (U-1695)US 9006256290d
- Mar 19, 2027patentUS 7612208*PED160d
- Mar 19, 2027patentUS 7612208*PED160d
- Sep 19, 2026compositionUS 7612208
- Sep 19, 2026compositionUS 7612208
- Apr 24, 2026patentUS 7253286*PED
- Apr 24, 2026patentUS 7253286*PED
- Oct 24, 2025compositionUS 7253286
- Oct 24, 2025compositionUS 7253286
FDA exclusivities (8)
- Oct 3, 2027PEDPediatric (6mo bonus)358d
- Oct 3, 2027PEDPediatric (6mo bonus)358d
- Apr 3, 2027M-14Method (3y)175d
- Apr 3, 2027M-14Method (3y)175d
- Feb 15, 2026PEDPediatric (6mo bonus)
- Feb 15, 2026PEDPediatric (6mo bonus)
- Aug 15, 2025ODE-196Orphan Drug (7y)
- Aug 15, 2025ODE-196Orphan Drug (7y)
News(1)
- Merck expands Welireg's use to broader set of kidney cancer patientsMerck’s Welireg won FDA approval on Friday for use in combination with Eisai’s Lenvima to treat certain kidney cancer patients. The combination will be available to patients with advanced renal cel…endpoints · 14d ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that